Advertisement
Screener

Spero Therapeutics, Inc. (SPRO) Deferred Tax Liabilities, Net

2.8 / 5 stars · 68/120 Roast Me

Spero Therapeutics, Inc. Deferred Tax Liabilities, Net

Spero Therapeutics, Inc. (SPRO) had Deferred Tax Liabilities, Net of $388.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-26.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities

us-gaap:DeferredTaxLiabilities · last filed 2026-03-26

  • 2025-12-31: Deferred Tax Liabilities, Net $388.00K.
  • 2024-12-31: Deferred Tax Liabilities, Net $816.00K.
Period endDeferred Tax Liabilities, Net
2025-12-31$388.00K
10-K · filed 2026-03-26
2024-12-31$816.00K
10-K · filed 2026-03-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cingulate Inc. (CING)United States$0.073B-2.64
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
Yarrow Bioscience, Inc. (YARW)United States$0.070B
OS Therapies Inc (OSTX)United States$0.076B-2.17
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17